AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16182162 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional anesthesia with 2% lidocaine and epinephrine, 1:100,000
Number of subjects: 18
Study 16182162 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates anesthesia with 2% lidocaine and epinephrine, 1:100,000
Number of subjects: 18
Study 16182162 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional anesthesia with plain 3% mepivacaine
Number of subjects: 18
Study 12398829 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (1 week later)
Number of subjects: 127
Study 12398829 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (2 weeks later)
Number of subjects: 127
Study 12398829 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (third test)
Number of subjects: 127
Study 12398829 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (negative response)
Number of subjects: 127
Study 9867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%, b.i.d. or q.i.d.
Number of subjects: 148
Study 9867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.1%, q.i.d.
Number of subjects: 148
Study 9867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.2%, q.i.d.
Number of subjects: 148
Study 9867336 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.3%, q.i.d.
Number of subjects: 148
Study 9867336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 7657740 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist [(imBzl)D‐His6, Pro9‐NEt]‐GnRH (D‐His) at doses of 0.01, 0.1, 1, and 10 micrograms/kg
Number of subjects: 12
Study 2710253 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 50
Study 2710253 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard care not specified)
Number of subjects: 50
Study 972138 — intervention group
Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 10
Study 972138 — intervention group
Group type: EXPERIMENTAL
Intervention: Limping (induced by a 0.5-cm wooden spike under the heel)
Number of subjects: 10
Study 31109313 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R plus acalabrutinib for six cycles followed by acalabrutinib maintenance
Number of subjects: 0
Study 31109313 — intervention group
Group type: COMPARATOR
Intervention: CHOP-R for six cycles
Number of subjects: 0
Study 31109313 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 0
Study 31109313 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R plus acalabrutinib
Number of subjects: 0
Study 31109313 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 0
Study 28236981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide (930μg as lipopeptide) subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Number of subjects: 172
Study 28236981 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously once weekly for 8 weeks, then every 6 weeks until disease progression or treatment withdrawal.
Number of subjects: 172
Study 25200879 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise and pain neurophysiology education
Number of subjects: 62
Study 25200879 — intervention group
Group type: COMPARATOR
Intervention: Aquatic exercise alone
Number of subjects: 62
Study 23403268 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 8831
Study 23403268 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8831
Study 21788267 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional neurological therapy
Number of subjects: 44
Study 21788267 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint induced therapy
Number of subjects: 44
Study 21788267 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic climbing
Number of subjects: 44
Study 19339558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion posterior cruciate-retaining total knee prosthesis
Number of subjects: 250
Study 19339558 — intervention group
Group type: COMPARATOR
Intervention: High-flexion posterior cruciate-substituting total knee prosthesis
Number of subjects: 250
Study 17163320 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnification chromoendoscopy (MCE) with indigo carmine dye staining
Number of subjects: 56
Study 17163320 — intervention group
Group type: EXPERIMENTAL
Intervention: MCE
Number of subjects: 56
Study 17163320 — intervention group
Group type: COMPARATOR
Intervention: Random biopsies
Number of subjects: 56
Study 14510624 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with negative inotropic agents (beta‐blockers, verapamil)
Number of subjects: 0
Study 14510624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical myectomy
Number of subjects: 0
Study 14510624 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous septal ablation
Number of subjects: 0
Study 14510624 — intervention group
Group type: COMPARATOR
Intervention: Dual chamber pacing
Number of subjects: 0
Study 14510624 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0
Study 14510624 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0
Study 11052410 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline treatment (3 mg/kg/day, optimized dosing)
Number of subjects: 21
Study 11052410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9074702 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (0.75, 1.5 and 3 pmol.kg-1.min-1 for 30 min each)
Number of subjects: 10
Study 9074702 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 7941677 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 27
Study 7941677 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 27
Study 3239425 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol, 150 mg subcutaneously
Number of subjects: 6
Study 3239425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding
Number of subjects: 6
Study 3239425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic distension to a volume of 600 ml
Number of subjects: 6
Study 3239425 — intervention group
Group type: EXPERIMENTAL
Intervention: 16,16-dimethyl prostaglandin E2, 80 micrograms
Number of subjects: 6
Study 30151941 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of intravenous immunoglobulins (IVIg) administered 1 week after the first course
Number of subjects: 0
Study 30151941 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of intravenous immunoglobulins (IVIg)
Number of subjects: 0
Study 30151941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 0
Study 28034536 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper oxide-impregnated textiles
Number of subjects: 0
Study 27479337 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinted design with bar units
Number of subjects: 40
Study 27479337 — intervention group
Group type: COMPARATOR
Intervention: Unsplinted design with ball attachments
Number of subjects: 40
Study 23839050 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan at dose level VI (240 mg/m²)
Number of subjects: 33
Study 23839050 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan at dose level VII (260 mg/m²)
Number of subjects: 33
Study 23839050 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (overall treatment)
Number of subjects: 33
Study 21963063 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronase and bicarbonate (Group B)
Number of subjects: 183
Study 21963063 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Group A)
Number of subjects: 183
Study 21963063 — intervention group
Group type: COMPARATOR
Intervention: Pronase, bicarbonate, and simethicone (Group C)
Number of subjects: 183
Study 18941779 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 48
Study 18941779 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/bcl‐xL AS‐ODNs
Number of subjects: 48
Study 18941779 — intervention group
Group type: COMPARATOR
Intervention: bcl‐xL AS‐ODNs (control)
Number of subjects: 48
Study 18941779 — intervention group
Group type: COMPARATOR
Intervention: Medium (control)
Number of subjects: 48
Study 16482073 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-rich diet (6.8 g/day)
Number of subjects: 37
Study 16482073 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA/DHA-rich diet (1.05 g EPA/day + 0.55 g DHA/day)
Number of subjects: 37
Study 16482073 — intervention group
Group type: COMPARATOR
Intervention: Control diet (oleic acid-rich diet)
Number of subjects: 37
Study 14872156 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic antagonists
Number of subjects: 0
Study 11741055 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for six weeks)
Number of subjects: 166
Study 11741055 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (800 cGy within 72 hours post-surgery)
Number of subjects: 166
Study 11741055 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 166
Study 9438487 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (5 mg) plus pseudoephedrine (120 mg) (L/P)
Number of subjects: 193
Study 9438487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 8426204 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide (VM26)/Cytarabine (Ara‐C)
Number of subjects: 120
Study 8426204 — intervention group
Group type: COMPARATOR
Intervention: Prednisone/Doxorubicin (PDN/DOX)
Number of subjects: 120
Study 8426204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol
Number of subjects: 120
Study 8426204 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment protocol
Number of subjects: 120
Study 3315542 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily by mouth)
Number of subjects: 10
Study 3315542 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (40 mg by mouth)
Number of subjects: 10
Study 28677325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-restricted group (5 hours TIB for 5 nights)
Number of subjects: 59
Study 28677325 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 hours TIB for 5 nights)
Number of subjects: 59
Study 27979028 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SQ-HDMI
Number of subjects: 106
Study 27979028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 SQ-HDMI
Number of subjects: 106
Study 27979028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 24136330 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 μg once-daily
Number of subjects: 586
Study 24136330 — intervention group
Group type: COMPARATOR
Intervention: FF 200 μg once-daily
Number of subjects: 586
Study 24136330 — intervention group
Group type: COMPARATOR
Intervention: FP 500 μg twice-daily
Number of subjects: 586
Study 22306007 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail invitations
Number of subjects: 270
Study 22306007 — intervention group
Group type: COMPARATOR
Intervention: Postal invitations
Number of subjects: 270
Study 22306007 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders for both invitation methods
Number of subjects: 270
Study 20026784 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib (60 mg)
Number of subjects: 67867
Study 20026784 — intervention group
Group type: COMPARATOR
Intervention: CETP single-nucleotide polymorphisms
Number of subjects: 67867
Study 18670328 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron
Number of subjects: 94
Study 18670328 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 94
Study 16009841 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses with a +2.00 diopter (D) addition
Number of subjects: 469
Study 16009841 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 469
Study 16009841 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses
Number of subjects: 469
Study 12649629 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily OROS methylphenidate (OROS MPH)
Number of subjects: 407
Study 11000370 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting of the abdominal wall (L)
Number of subjects: 150
Study 11000370 — intervention group
Group type: COMPARATOR
Intervention: Nonlifting of the abdominal wall (NL)
Number of subjects: 150
Study 8851737 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial span task
Number of subjects: 0
Study 8851737 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading span test
Number of subjects: 0
Study 8851737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference paradigm in Experiment 2
Number of subjects: 0
Study 8101589 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth monitoring package (GMP) intervention villages
Number of subjects: 1100
Study 8101589 — intervention group
Group type: COMPARATOR
Intervention: Non-growth monitoring package (NGM) intervention villages
Number of subjects: 1100
Study 2427840 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg daily for 2 weeks, then 400 mg daily for 2 weeks, and 600 mg daily for another 2 weeks for non-responders
Number of subjects: 190
Study 2427840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 30356303 — intervention group
Group type: EXPERIMENTAL
Intervention: Text classification using a Naive‐Bayes machine‐learning algorithm
Number of subjects: 100
Study 30356303 — intervention group
Group type: COMPARATOR
Intervention: Control group of 54 randomly selected texts from other periods of Virginia Woolf's life
Number of subjects: 100
Study 27422705 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous reduction, cannulated screw fixation and calcium sulfate cement (PR+CSC)
Number of subjects: 80
Study 27422705 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive sinus tarsi approach and plate fixation (MISTA)
Number of subjects: 80
Study 25151098 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous salvaged blood collected by Sangvia™ Blood Salvage System
Number of subjects: 164
Study 25151098 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic red cell concentrates
Number of subjects: 164
Study 25151098 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusions
Number of subjects: 164
Study 25151098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of autologous blood
Number of subjects: 164
Study 25151098 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative haemoglobin concentration
Number of subjects: 164
Study 22873356 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 317
Study 22873356 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 317
Study 22873356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 317
Study 20018797 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpalatal distraction (TPD) as a bone‐borne device
Number of subjects: 30
Study 20018797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax appliance as a tooth‐borne device
Number of subjects: 30
Study 20018797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no expansion appliances)
Number of subjects: 30
Study 18412271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PCI and optimal medical therapy (OMT)
Number of subjects: 0
Study 18412271 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 0
Study 18412271 — intervention group
Group type: COMPARATOR
Intervention: Crossover from OMT to PCI
Number of subjects: 0
Study 18412271 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant untreated ischemia
Number of subjects: 0
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone-based adhesive (Prime & Bond NT) with blotted dry technique
Number of subjects: 120
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based adhesive (Syntac Single Component)
Number of subjects: 120
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Water- and ethanol-based adhesive (Single Bond)
Number of subjects: 120
Study 15997932 — intervention group
Group type: COMPARATOR
Intervention: Control group (overwet technique)
Number of subjects: 120
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-dried for 30 seconds
Number of subjects: 120
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-dried for 3 seconds
Number of subjects: 120
Study 15997932 — intervention group
Group type: EXPERIMENTAL
Intervention: Blotted dry
Number of subjects: 120
Study 12900600 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeroform dressing
Number of subjects: 19
Study 12900600 — intervention group
Group type: COMPARATOR
Intervention: Jelonet dressing
Number of subjects: 19
Study 12900600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reharvested donor sites
Number of subjects: 19
Study 12900600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reepithelialized donor-site epidermis
Number of subjects: 19
Study 10385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 5 weeks
Number of subjects: 7
Study 10385633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8689882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilest
Number of subjects: 100
Study 8689882 — intervention group
Group type: EXPERIMENTAL
Intervention: Femodeen
Number of subjects: 100
Study 8689882 — intervention group
Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 100
Study 8689882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercilon
Number of subjects: 100
Study 1997850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 to 0 mg per day for 8 days)
Number of subjects: 93
Study 1997850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 1997850 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 93
Study 6724077 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (plasma exchange)
Number of subjects: 7
Study 30460483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (SD)
Number of subjects: 51
Study 30460483 — intervention group
Group type: COMPARATOR
Intervention: Sleep control (SC)
Number of subjects: 51
Study 30460483 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression (both groups)
Number of subjects: 51
Study 30321201 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy including desensitization manoeuvres of the central nervous system (n = 60)
Number of subjects: 120
Study 30321201 — intervention group
Group type: COMPARATOR
Intervention: Surgery (n = 60)
Number of subjects: 120
Study 26725717 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV detection in samples from enrollment, 6‐, 12‐, and 18‐month visits
Number of subjects: 120
Study 26725717 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of new HPV infections
Number of subjects: 120
Study 26725717 — intervention group
Group type: EXPERIMENTAL
Intervention: Point prevalence of vaccine types HPV‐6,‐11,‐16, and ‐18
Number of subjects: 120
Study 25409438 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (N=561)
Number of subjects: 561
Study 25409438 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (N=86)
Number of subjects: 561
Study 25409438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N=561)
Number of subjects: 561
Study 21992596 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day S‐(‐)equol for 12 weeks
Number of subjects: 160
Study 21992596 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 160
Study 20055340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patella tendon-bone autograft
Number of subjects: 173
Study 20055340 — intervention group
Group type: COMPARATOR
Intervention: Bone-patella tendon-bone allograft
Number of subjects: 173
Study 18091270 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI-based functional neuronavigation
Number of subjects: 238
Study 18091270 — intervention group
Group type: COMPARATOR
Intervention: Routine neuronavigation (Control)
Number of subjects: 238
Study 15810623 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg bid
Number of subjects: 323
Study 15810623 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid
Number of subjects: 323
Study 15810623 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with antibiotic resistance
Number of subjects: 323
Study 15810623 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with smoking history
Number of subjects: 323
Study 11999127 — intervention group
Group type: COMPARATOR
Intervention: Sodium caprate added during the second period of perfusion (100-200 min) at pH 6.0
Number of subjects: 6
Study 11999127 — intervention group
Group type: COMPARATOR
Intervention: Sodium caprate added during the second period of perfusion (100-200 min) at pH 7.4
Number of subjects: 6
Study 11999127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium caprate
Number of subjects: 6
Study 10024084 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO) therapy
Number of subjects: 7
Study 10024084 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 7
Study 8652974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC) 100 ml three times a day for 3 consecutive days
Number of subjects: 75
Study 8652974 — intervention group
Group type: COMPARATOR
Intervention: Bovine colostrum (control)
Number of subjects: 75
Study 8652974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmune bovine colostrum (HBC)
Number of subjects: 75
Study 2181565 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (40 mg/day)
Number of subjects: 15
Study 2181565 — intervention group
Group type: EXPERIMENTAL
Intervention: low salt diet (5 g of salt/day) and nifedipine
Number of subjects: 15